Union Minister Dr. Jitendra Singh launched BIRSA 101, India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease (SCD), on November 19, 2025. Developed by CSIR-Institute of Genomics and Integrative Biology (IGIB) in partnership with the Serum Institute of India, it is named after tribal leader Birsa Munda.

BIRSA 101 uses CRISPR technology to correct the mutation causing sickle-shaped red blood cells, offering a potential one-time lifelong cure. While global gene therapies for SCD cost ₹20-25 crore, BIRSA 101 aims to cost around ₹50 lakh. Clinical trials with participants from MP, Chhattisgarh, and Jharkhand are set to begin in 2026. SCD disproportionately affects tribal populations including Gond, Munda, Bhil, and Santal communities.